Teva to Acquire Labrys Biologics, Inc.: Novel Migraine Prophylaxis Treatment for up to $825 million

–  Adds Significant New Dimension to Teva’s Growing Pain Care Franchise. Peak sales potential of $2-3 billion. – –   Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) and More...